Nocdurna is a drug owned by Ferring Pharmaceuticals Inc. It is protected by 11 US drug patents filed from 2018 to 2024. Out of these, 4 drug patents are active and 7 have expired. Based on its patents and exclusivities, its generic launch date is estimated to be Apr 13, 2030. Details of Nocdurna's patents and their expiration are given in the table below.

A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Nocdurna's patents.

Latest Legal Activities on Nocdurna's Patents

Given below is the list of recent legal activities going on the following patents of Nocdurna.

Activity	Date	Patent Number
Critical Events for all Patents
Payment of Maintenance Fee, 8th Year, Large Entity	20 Jun, 2023	US9220747
Payment of Maintenance Fee, 4th Year, Large Entity	22 Nov, 2022	US10307459
Payment of Maintenance Fee, 12th Year, Large Entity	15 Nov, 2022	US7947654
Payment of Maintenance Fee, 4th Year, Large Entity	17 May, 2022	US10137167
Payment of Maintenance Fee, 8th Year, Large Entity	01 Feb, 2022	US8802624
Payment of Maintenance Fee, 4th Year, Large Entity	09 Nov, 2021	US9974826
Payment of Maintenance Fee, 4th Year, Large Entity	07 Sep, 2021	US9919025
Patent Issue Date Used in PTA Calculation Critical	01 Jun, 2021	US11020448
Recordation of Patent Grant Mailed Critical	01 Jun, 2021	US11020448
Email Notification Critical	14 May, 2021	US11020448

While patent expiration is one way of estimating the generic date of a drug, if a patent gets invalidated somehow, the generic of the drug may arrive early. Being aware of all relevant patents can help in avoiding legal pitfalls. Given below are details of the litigation history of Nocdurna and ongoing litigations to help you estimate the early arrival of Nocdurna generic.

Nocdurna's Litigations

Nocdurna been subject to various legal proceedings, including patent litigations. The earliest legal proceeding was initiated on Apr 16, 2015, against patent number US9974826. The petitioner , challenged the validity of this patent, with Bjarke Mimer Klein et al as the respondent. Click below to track the latest information on how companies are challenging Nocdurna's patents.

Patent	Proceeding Filing Date	Status	Respondent	Petitioner
Live updates
US9974826	April, 2015	Decision (07 Jun, 2017)	Bjarke Mimer Klein et al

FDA has granted some exclusivities to Nocdurna. Till the time these exclusivities are active, no other company can market a generic or bioequivalent version of Nocdurna, regardless of the status of it's patents. These exclusivities hence play a crucial role in delaying the generic launch. Given below are details of the exclusivities granted to Nocdurna.

Stay ahead of others in designing the generic launch strategy of these 5 blockbuster drugs expiring in next 5 years.

Get the exclusive patent insights now. Don't be the last to know.

Download Report

Several oppositions have been filed on Nocdurna's European patents. EP oppositions can significantly impact the timeline for the generic launch of drugs. If an opposition results in the revocation or amendment of a patent, it can shorten the exclusivity period of the original drug. This can lead to an earlier entry of generic versions into the market. To help you estimate the potential early arrival of Nocdurna's generic, the next section provides detailed information on ongoing and past EP oppositions related to Nocdurna patents.

Nocdurna's Oppositions Filed in EPO

Nocdurna has faced multiple oppositions in the European Patent Office. The earliest opposition was filed on Nov 11, 2014, by Gebro Pharma Gmbh. This opposition was filed on patent number EP09751584A. Click below to reveal the latest opposition data.

Application	Filing Date	Opposition Party	Legal Status
Live updates
EP09751584A	Nov, 2014	Gebro Pharma GmbH	Patent maintained as amended

US patents provide insights into the exclusivity only within the United States, but Nocdurna is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Nocdurna's family patents as well as insights into ongoing legal events on those patents.

Nocdurna's Family Patents

Nocdurna has patent protection in a total of 35 countries. It's US patent count contributes only to 16.1% of its total global patent coverage. 10 countries have all of their patents expired or invalidated which has opened up potential generic launch opportunities in these countries. Click below to unlock the full patent family tree for Nocdurna.

Full family tree

Generic Launch

About Nocdurna

Nocdurna is a drug owned by Ferring Pharmaceuticals Inc. It is used for treating nocturia in adults with nocturnal polyuria by monitoring serum sodium concentration. Nocdurna uses Desmopressin Acetate as an active ingredient. Nocdurna was launched by Ferring Pharms Inc in 2018.